Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

The fact the language is being tested is one sign of a potential imbalance in the loan market, a critical source of funding ...

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

The stock's fall snapped a five-day winning streak.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

The event will pave the way for new commitments from First Ladies, ministers, and the Merck Foundation team to create more ...

A bounding pulse is when your heart beats strongly. You may feel your pulse in your neck, wrist, or foot. Here’s why it ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.